Avoid common mistakes on your manuscript.
The authors of the above-mentioned paper noticed a few errors in the text, as reported. In the ‘Pharmacokinetics’ section, with regards to the C1 inhibitor, Cinryze® (ViroPharma Inc.), the maximum plasma concentration (Cmax) (units/mL) values should read 0.68 ± 0.08 (n = 12) versus 0.85 ± 0.12 (n = 13), and not 0.68 ± 0.08 (n = 12) versus 0.33 ± 0.20 (n = 12), as reported. The authors regret this error, and thank Springer Healthcare for publishing the correction.
Additional information
This article is published with open access at Springerlink.com
The online version of the original article can be found at http://dx.doi.org/10.1007/s13554-012-0002-5
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Farkas, H., Varga, L. Erratum to: Human Plasma-Derived, Nanofiltered C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting From C1-Inhibitor Deficiency. Biol Therapy 2, 4 (2012). https://doi.org/10.1007/s13554-012-0004-3
Published:
DOI: https://doi.org/10.1007/s13554-012-0004-3